These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38850838)

  • 1. Effect of Metformin on systemic chemokine responses during anti-tuberculosis chemotherapy.
    Pavan Kumar N; Padmapriyadarsini C; Nancy A; Tamizhselvan M; Mohan A; Reddy D; Ganga Devi NP; Rathinam P; Jeyadeepa B; Shandil RK; Guleria R; Singh M; Babu S
    Tuberculosis (Edinb); 2024 Jun; 148():102523. PubMed ID: 38850838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis.
    Padmapriydarsini C; Mamulwar M; Mohan A; Shanmugam P; Gomathy NS; Mane A; Singh UB; Pavankumar N; Kadam A; Kumar H; Suresh C; Reddy D; Devi P; Ramesh PM; Sekar L; Jawahar S; Shandil RK; Singh M; Menon J; Guleria R
    Clin Infect Dis; 2022 Aug; 75(3):425-434. PubMed ID: 34849651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma chemokines are biomarkers of disease severity, higher bacterial burden and delayed sputum culture conversion in pulmonary tuberculosis.
    Kumar NP; Moideen K; Nancy A; Viswanathan V; Shruthi BS; Sivakumar S; Natarajan M; Kornfeld H; Babu S
    Sci Rep; 2019 Dec; 9(1):18217. PubMed ID: 31796883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy.
    Kumar NP; Moideen K; Nancy A; Viswanathan V; Shruthi BS; Sivakumar S; Hissar S; Kornfeld H; Babu S
    BMC Infect Dis; 2019 Dec; 19(1):1039. PubMed ID: 31818258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment.
    Kumar NP; Moideen K; Viswanathan V; Shruthi BS; Sivakumar S; Menon PA; Kornfeld H; Babu S
    BMC Infect Dis; 2018 Jul; 18(1):345. PubMed ID: 30045688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co-morbidity.
    Kumar NP; Moideen K; Bhootra Y; Nancy A; Viswanathan V; Shruthi BS; Sivakumar S; Natarajan M; Kornfeld H; Babu S
    Immunology; 2019 Mar; 156(3):249-258. PubMed ID: 30427060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma chemokines as immune biomarkers for diagnosis of pediatric tuberculosis.
    Kumar NP; Hissar S; Thiruvengadam K; Banurekha VV; Balaji S; Elilarasi S; Gomathi NS; Ganesh J; Aravind MA; Baskaran D; Tripathy S; Swaminathan S; Babu S
    BMC Infect Dis; 2021 Oct; 21(1):1055. PubMed ID: 34635070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis - Diabetes co-morbidity.
    Kumar NP; Moideen K; Viswanathan V; Sivakumar S; Hissar S; Kornfeld H; Babu S
    J Clin Tuberc Other Mycobact Dis; 2021 May; 23():100237. PubMed ID: 33997311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
    Padmapriyadarsini C; Bhavani PK; Natrajan M; Ponnuraja C; Kumar H; Gomathy SN; Guleria R; Jawahar SM; Singh M; Balganesh T; Swaminathan S
    BMJ Open; 2019 Mar; 9(3):e024363. PubMed ID: 30826761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis.
    Kumar AKH; Kadam A; Karunaianantham R; Tamizhselvan M; Padmapriyadarsini C; Mohan A; Jeyadeepa B; Radhakrishnan A; Singh UB; Bapat S; Mane A; Kumar P; Mamulwar M; Bhavani PK; Haribabu H; Rath N; Guleria R; Khan AM; Menon J;
    Ther Drug Monit; 2024 Jun; 46(3):370-375. PubMed ID: 38019456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filarial Coinfection Is Associated With Higher Bacterial Burdens and Altered Plasma Cytokine and Chemokine Responses in Tuberculous Lymphadenitis.
    Kathamuthu GR; Munisankar S; Banurekha VV; Nair D; Sridhar R; Babu S
    Front Immunol; 2020; 11():706. PubMed ID: 32373129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexistent Helminth Infection-Mediated Modulation of Chemokine Responses in Latent Tuberculosis.
    Rajamanickam A; Munisankar S; Bhootra Y; Dolla CK; Nutman TB; Babu S
    J Immunol; 2019 Mar; 202(5):1494-1500. PubMed ID: 30651341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Eicosanoid Levels in Tuberculosis and Tuberculosis-Diabetes Co-morbidity Are Associated With Lung Pathology and Bacterial Burden.
    Pavan Kumar N; Moideen K; Nancy A; Viswanathan V; Shruthi BS; Shanmugam S; Hissar S; Kornfeld H; Babu S
    Front Cell Infect Microbiol; 2019; 9():335. PubMed ID: 31632923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heightened systemic levels of anti-inflammatory cytokines in pulmonary tuberculosis and alterations following anti-tuberculosis treatment.
    Moideen K; Kumar NP; Bethunaickan R; Banurekha VV; Nair D; Babu S
    Cytokine; 2020 Mar; 127():154929. PubMed ID: 31811994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of HIV coinfection, HAART and TB treatment on cytokine/chemokine responses to Mycobacterium tuberculosis (Mtb) antigens in active TB patients and latently Mtb infected individuals.
    Kassa D; de Jager W; Gebremichael G; Alemayehu Y; Ran L; Fransen J; Wolday D; Messele T; Tegbaru B; Ottenhoff TH; van Baarle D
    Tuberculosis (Edinb); 2016 Jan; 96():131-40. PubMed ID: 26631832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withaferin A Protects against Primary and Recurrent Tuberculosis by Modulating Mycobacterium-Specific Host Immune Responses.
    Kumari A; Pahuja I; Negi K; Ghoshal A; Mukopadhyay S; Agarwal M; Mathew B; Maras JS; Chaturvedi S; Bhaskar A; Dwivedi VP
    Microbiol Spectr; 2023 Mar; 11(2):e0058323. PubMed ID: 36916966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients.
    Wolday D; Tegbaru B; Kassu A; Messele T; Coutinho R; van Baarle D; Miedema F
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):265-71. PubMed ID: 15980685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.
    Degner NR; Wang JY; Golub JE; Karakousis PC
    Clin Infect Dis; 2018 Jan; 66(2):198-205. PubMed ID: 29325084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dzherelo (Immunoxel) as adjunctive therapy to standard antituberculosis treatment in patients with pulmonary tuberculosis: a systematic review and meta-analysis of clinical trials.
    Kitenge M; Phiri B; Pheeha SM; Ogunrombi M; Nyasulu PS
    Syst Rev; 2021 May; 10(1):157. PubMed ID: 34039420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.